BioNexus Gene Lab マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Lee Tan

最高経営責任者

US$16.0k

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	less than a year

経営陣の近況

Recent updates

BioNexus Gene Lab Corp. (NASDAQ:BGLC) Stocks Shoot Up 234% But Its P/S Still Looks Reasonable

Feb 14

CEO（最高経営責任者

Lee Tan (41 yo)

less than a year

在職期間

US$16,000

報酬

Mr. Su-Leng Tan, also known as Lee, is CEO & Director of BioNexus Gene Lab Corp. from December 11, 2023 and also serves as its Acting Chief Financial Officer and Secretary. Mr. Tan was Chief Operating Offi...

取締役

名称	ポジション	在職期間	報酬	所有権
Su-Leng Tan	CEO, Acting CFO	less than a year	US$16.00k	データなし
Chee Yap	Independent Non-Executive Director	2.7yrs	US$3.00k	データなし
Muhammad bin Abdul Hamid	Independent Director	less than a year	データなし	データなし

0.9yrs

平均在職期間

48yo

平均年齢

経験豊富なボード: BGLCの取締役会は経験豊富ではない ( 0.9年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

BioNexus Gene Lab マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Bionexus Gene Lab Corp. Announces Resignation of Wei Foong Lim and Koon Wai Wong as Members of the Board of Directors and Member of the Audit Committee, and A Member of the Corporate Governance and Nominating Committee

BioNexus Gene Lab Corp., Annual General Meeting, Oct 04, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

BioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as the Chief Executive Officer

Recent updates

BioNexus Gene Lab Corp. announced delayed 10-Q filing

BioNexus Gene Lab Submits Formal Request for Hearing Before Nasdaq Hearings Panel to Appeal the Delisting Determination

Bionexus Gene Lab Corp. Announces Resignation of Wei Foong Lim and Koon Wai Wong as Members of the Board of Directors and Member of the Audit Committee, and A Member of the Corporate Governance and Nominating Committee

BioNexus Gene Lab Corp., Annual General Meeting, Oct 04, 2024

Second quarter 2024 earnings released: US$0.005 loss per share (vs US$0.018 loss in 2Q 2023)

High number of new and inexperienced directors

The Nasdaq Stock Market Determines BioNexus Gene Lab Eligible for an Additional 180 Calendar Day Extension Period or Until November 4, 2024 to Regain Compliance with Minimum Bid Price Per Share with Nasdaq Continued Listing Rule 5550(a)(2)

BioNexus Gene Lab Corp. announced delayed annual 10-K filing

BioNexus Gene Lab Corp. (NASDAQ:BGLC) Stocks Shoot Up 234% But Its P/S Still Looks Reasonable

High number of new and inexperienced directors

Soo Kow Lai Provides Information to Shareholders of BioNexus Gene Lab Corp

BioNexus Gene Lab Corp. announced delayed 10-Q filing

BioNexus Gene Lab Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Per Share with Nasdaq Continued Listing Rule 5550(a)(2)

High number of new and inexperienced directors

BioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as the Chief Executive Officer

BioNexus Gene Lab Corp. Announces Resignation of Sook Keng Yeoh as Chief Executive Officer

BioNexus Gene Lab Corp. Announces Executive Changes

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.001 loss per share (vs US$0.01 loss in 2Q 2022)

New minor risk - Shareholder dilution

High number of new and inexperienced directors

BioNexus Gene Lab Corporation has filed an IPO in the amount of $17.25 million.

Bionexus Gene Lab Corporation Announces Management Changes

BioNexus Gene Lab Corporation announced delayed annual 10-K filing

BioNexus Gene Lab Corporation announced delayed 10-Q filing

BioNexus Gene Lab Corporation (OTCPK:BGLC) agreed to acquire Chemrex Corporation Sdn. Bhd.

CEO（最高経営責任者

在職期間

報酬

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14